A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer
Clinical trial NCT05444374 · UNKNOWN
Trial details
- NCT number
- NCT05444374
- Sponsor
- Sichuan Cancer Hospital and Research Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-01
- Primary completion
- 2024-09-30
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.